The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy
Open accessAbstract
Spurred by recent progress in medicinal chemistry, numerous lead compounds have sprung up in the past few years, although the majority are hindered by hydrophobicity, which greatly challenges druggability. In an effort to assess the potential of platinum (Pt) candidates, the nanosizing approach to alter the pharmacology of hydrophobic Pt(IV) prodrugs in discovery and development settings is described. The construction of a self-assembled nanoparticle (NP) platform, composed of amphiphilic lipid-polyethylene glycol (PEG) for effective delivery of Pt(IV) prodrugs capable of resisting thiol-mediated detoxification through a glutathione (GSH)-exhausting effect, offers a promising route to synergistically improving safety and efficacy. After a systematic screening, the optimized NPs (referred to as P6 NPs) exhibited small particle size (99.3 nm), high Pt loading (11.24%), reliable dynamic stability (∼7 days), and rapid redox-triggered release (∼80% in 3 days). Subsequent experiments on cells support the emergence of P6 NPs as a highly effective means of transporting a lethal dose of cargo across cytomembranes through macropinocytosis. Upon reduction by cytoplasmic reductants, particularly GSH, P6 NPs under disintegration released sufficient active Pt(II) metabolites, which covalently bound to target DNA and induced significant apoptosis. The PEGylation endowed P6 NPs with in vivo longevity and tumor specificity, which were essential to successfully inhibiting the growth of cisplatin-sensitive and -resistant xenograft tumors, while effectively alleviating toxic side-effects associated with cisplatin. P6 NPs are, therefore, promising for overcoming the bottleneck in the development of Pt drugs for oncotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Self-citationMatsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Self-citationThe resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Self-citationBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Self-citationJohnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Designing dendrimers for biological applications
Lee, C. C., MacKay, J. A., Fréchet, J. M. J., & Szoka, F. C. (2005) · Nature Biotechnology · doi:10.1038/nbt1171 · Cited by 2,043
Cyclodextrin-based pharmaceutics: past, present and future
Davis, M. E., & Brewster, M. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1576 · Cited by 1,996
Dynamic Combinatorial Chemistry
Corbett, P. T., Leclaire, J., Vial, L., West, K. R., Wietor, J.-L., Sanders, J. K. M., & Otto, S. (2006) · Chemical Reviews · doi:10.1021/cr020452p · Cited by 1,922
Jares-Erijman, E. A., & Jovin, T. M. (2003) · Nature Biotechnology · doi:10.1038/nbt896 · Cited by 1,824
Current Status of Platinum-Based Antitumor Drugs
Wong, E., & Giandomenico, C. M. (1999) · Chemical Reviews · doi:10.1021/cr980420v · Cited by 1,800
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Self-citationLin, L., Song, J., Song, L., Ke, K., Liu, Y., Zhou, Z., Shen, Z., Li, J., Yang, Z., Tang, W., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201712027 · Cited by 1,466
Salt formation to improve drug solubility
Serajuddin, A. T. M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.010 · Cited by 1,425
Lu, Y., Aimetti, A. A., Langer, R., & Gu, Z. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.75 · Cited by 1,421
Solubilizing Excipients in Oral and Injectable Formulations
Strickley, R. G. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000016235.32639.23 · Cited by 1,415
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., & Anderson, M. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3070 · Cited by 925
Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876
Vaccinia Virus Uses Macropinocytosis and Apoptotic Mimicry to Enter Host Cells
Mercer, J., & Helenius, A. (2008) · Science · doi:10.1126/science.1155164 · Cited by 781
Novel trends in high-throughput screening
Mayr, L. M., & Bojanic, D. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.08.004 · Cited by 694
Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels.
Kuppusamy, P., Li, H., Ilangovan, G., Cardounel, A. J., Zweier, J. L., Yamada, K., Krishna, M. C., & Mitchell, J. B. (2002) · PubMed · Cited by 685
Feazell, R. P., Nakayama-Ratchford, N., Dai, H., & Lippard, S. J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073231f · Cited by 616
Hu, X., Hu, J., Tian, J., Ge, Z., Zhang, G., Luo, K., & Liu, S. (2013) · Journal of the American Chemical Society · doi:10.1021/ja409686x · Cited by 605
Lee, H., Lee, E., Kim, D. K., Jang, N. K., Jeong, Y. Y., & Jon, S. (2006) · Journal of the American Chemical Society · doi:10.1021/ja061529k · Cited by 594
Drug delivery strategies for poorly water-soluble drugs
Fahr, A., & Liu, X. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.403 · Cited by 568
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Wang, C., Sun, W., Ye, Y., Hu, Q., Bomba, H. N., & Gu, Z. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0011 · Cited by 526
Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity
Kroll, A. V., Fang, R. H., Jiang, Y., Zhou, J., Wei, X., Yu, C. L., Gao, J., Luk, B. T., Dehaini, D., Gao, W., et al. (2017) · Advanced Materials · doi:10.1002/adma.201703969 · Cited by 501
ROS‐Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy
Xu, X., Saw, P. E., Tao, W., Li, Y., Ji, X., Bhasin, S., Liu, Y., Ayyash, D., Rasmussen, J., Huo, M., et al. (2017) · Advanced Materials · doi:10.1002/adma.201700141 · Cited by 499
Self-citationLipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
Dong, Y., Love, K. T., Dorkin, J. R., Sirirungruang, S., Zhang, Y., Chen, D., Bogorad, R. L., Yin, H., Chen, Y., Vegas, A. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322937111 · Cited by 488
Self-citationQualitative and Quantitative Analysis of Nonneoplastic Lesions in Toxicology Studies
Shackelford, C., Long, G., Wolf, J., Okerberg, C., & Herbert, R. (2002) · Toxicologic Pathology · doi:10.1080/01926230252824761 · Cited by 427
Faubel, S., Lewis, E. C., Reznikov, L., Ljubanovic, D., Hoke, T. S., Somerset, H., Oh, D.-J., Lu, L., Klein, C. L., Dinarello, C. A., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.119792 · Cited by 399
Transcription-independent p53 apoptosis: an alternative route to death
Speidel, D. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.10.002 · Cited by 356
Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging
Yang, J., Chen, H., Vlahov, I. R., Cheng, J.-X., & Low, P. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601455103 · Cited by 318
Reduction and Anticancer Activity of Platinum(IV) Complexes
Choi, S., Filotto, C., Bisanzo, M., Delaney, S., Lagasee, D., Whitworth, J. L., Jusko, A., Li, C., Wood, N. A., Willingham, J., et al. (1998) · Inorganic Chemistry · doi:10.1021/ic971047x · Cited by 270
Sun, W., Li, S., Häupler, B., Liu, J., Jin, S., Steffen, W., Schubert, U. S., Butt, H., Liang, X., & Wu, S. (2017) · Advanced Materials · doi:10.1002/adma.201603702 · Cited by 251
Photoswitchable nanoparticles for in vivo cancer chemotherapy
Tong, R., Chiang, H. H., & Kohane, D. S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315336110 · Cited by 227
Lewis, A. D., Hayes, J. D., & Wolf, C. R. (1988) · Carcinogenesis · doi:10.1093/carcin/9.7.1283 · Cited by 223
Combating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery System
Min, Y., Mao, C., Chen, S., Ma, G., Wang, J., & Liu, Y. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201562 · Cited by 222
Self-citationLing, X., Chen, X., Riddell, I. A., Tao, W., Wang, J., Hollett, G., Lippard, S. J., Farokhzad, O. C., Shi, J., & Wu, J. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01924 · Cited by 209
Self-citationA Role for Polymerase η in the Cellular Tolerance to Cisplatin-Induced Damage
Albertella, M. R., Green, C. M., Lehmann, A. R., & O'Connor, M. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1095 · Cited by 207
Excipient–Drug Interactions in Parenteral Formulations
Akers, M. J. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10154 · Cited by 202
Combating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery System
Min, Y., Mao, C., Chen, S., Ma, G., Wang, J., & Liu, Y. (2012) · Angewandte Chemie · doi:10.1002/ange.201201562 · Cited by 181
Self-citationZhang, F., Ni, Q., Jacobson, O., Cheng, S., Liao, A., Wang, Z., He, Z., Yu, G., Song, J., Ma, Y., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201801984 · Cited by 152
Gramatica, P., Papa, E., Luini, M., Monti, E., Gariboldi, M. B., Ravera, M., Gabano, E., Gaviglio, L., & Osella, D. (2010) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-010-0676-4 · Cited by 137
Araki, N., Egami, Y., Watanabe, Y., & Hatae, T. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.02.012 · Cited by 122
The Mitochondrial Death Pathway
Chalah, A., & Khosravi‐Far, R. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_3 · Cited by 119
Zhang, X., Angsantikul, P., Man, Y. M., Zhuang, J., Zhang, Q., Wei, X., Jiang, Y., Zhang, Y., Dehaini, D., Chen, M., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707598 · Cited by 116
Self-citationSmart and hyper-fast responsive polyprodrug nanoplatform for targeted cancer therapy
Xu, X., Cheng, Y.-J., Wu, J., Cheng, H. B., Cheng, S., Zhuo, R., & Zhang, X. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.10.056 · Cited by 95
Lee, D. Y., Kim, J. Y., Lee, Y., Lee, S., Miao, W., Kim, H. S., Min, J., & Jon, S. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707137 · Cited by 91
Gadducci, A., Cosio, S., Muraca, S., & Genazzani, A. R. (2002) · PubMed · Cited by 75
Relay Drug Delivery for Amplifying Targeting Signal and Enhancing Anticancer Efficacy
Hu, Q., Sun, W., Qian, C., Bomba, H. N., Xin, H., & Gu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201605803 · Cited by 66
HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer
Liu, Y., Bernauer, A. M., Yingling, C. M., & Belinsky, S. A. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs142 · Cited by 65
The Effect of Ligand Lipophilicity on the Nanoparticle Encapsulation of Pt(IV) Prodrugs
Johnstone, T. C., & Lippard, S. J. (2013) · Inorganic Chemistry · doi:10.1021/ic4010642 · Cited by 60
Bassett, E., Vaisman, A., Leeman, K. T., McCall, C. M., Masutani, C., Hanaoka, F., & Chaney, S. G. (2002) · DNA repair · doi:10.1016/s1568-7864(02)00150-7 · Cited by 48
Time course of cisplatin-induced nephrotoxicity and hepatotoxicity
Pezeshki, Z., Khosravi, A., Nekuei, M., Khoshnood, S., Zandi, E., Eslamian, M., Talebi, A., Emami, S. N.-E.-D., & Nematbakhsh, M. (2017) · Journal of Nephropathology · doi:10.15171/jnp.2017.28 · Cited by 46
Zanellato, I., Bonarrigo, I., Colangelo, D., Gabano, E., Ravera, M., Alessio, M., & Osella, D. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.07.018 · Cited by 45
Ling, X., Shen, Y., Sun, R., Zhang, M., Li, C., Mao, J., Xing, J., Sun, C., & Tu, J. (2014) · Polymer Chemistry · doi:10.1039/c4py01592d · Cited by 45
Self-citationMazzoni, F., Cecere, F. L., Meoni, G., Giuliani, C., Boni, L., Camerini, A., Lucchesi, S., Martella, F., AMOROSO, D., Lucherini, E., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.018 · Cited by 37
Automated synthesis: new tools for the organic chemist
Hird, N. (1999) · Drug Discovery Today · doi:10.1016/s1359-6446(99)01337-9 · Cited by 36
Ling, X., Zhao, C., Huang, L., Wang, Q., Tu, J., Shen, Y., & Sun, C. (2015) · RSC Advances · doi:10.1039/c5ra16757d · Cited by 25
Self-citation
Cited by
Niu, B., Liao, K., Zhou, Y., Wen, T., Quan, G., Pan, X., & Wu, C. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121110 · Cited by 1,168
Role of Glutathione in Cancer: From Mechanisms to Therapies
Kennedy, L., Sandhu, J. K., Harper, M.-E., & Cuperlovic-Culf, M. (2020) · Biomolecules · doi:10.3390/biom10101429 · Cited by 880
Engineering nanomedicine for glutathione depletion-augmented cancer therapy
Xiong, Y., Xiao, C., Li, Z., & Yang, X. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00718h · Cited by 692
Natural biodegradable polymers based nano-formulations for drug delivery: A review
George, A., Shah, P. A., & Shrivastav, P. S. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.03.011 · Cited by 548
Tailoring the Swelling‐Shrinkable Behavior of Hydrogels for Biomedical Applications
Feng, W., & Wang, Z. (2023) · Advanced Science · doi:10.1002/advs.202303326 · Cited by 548
Metadata
- Authors
- Ling, X., Tu, J., Wang, J., Shajii, A., Kong, N., Feng, C., Zhang, Y., Yu, M., Xie, T., Bharwani, Z., Aljaeid, B. M., Shi, B., Tao, W., & Farokhzad, O. C.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-11-28
- Volume
- 13
- Issue
- 1
- Pages
- 357-370
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2902946041
- Cited by
- 263
- References
- 64
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.